CD274 and non-small cell lung carcinoma: The efficacy of pembrolizumab was evaluated in TKI-naïve NSCLC patients with EGFR mutation and PD-L1 positive tumors. None of the patients with EGR-mutant NSCLC responded. Enrollment was ceased due to lack of efficacy after 11 of the 25 planned patients were treated.